Skip to content
lsd.com
Unknown statusPhase 2 / Phase 3

Emergency Ketamine Treatment of Suicidal Ideation

NCT02183272 · University of Cincinnati

Closed to entry
Status
Not accepting participants
Phase 2 / Phase 3
Phase
60
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

The objective of the current program of research will be to test whether intranasal ketamine treatment is more effective than placebo in reducing suicidal ideation in suicidal patients presenting for acute treatment in emergency department settings. Secondary objectives will test the effect of genotypic differences in the mu opioid receptor on efficacy of ketamine and the correlation of speech patterns and facial movement patterns with subjective reductions in suicidal ideation after ketamine treatment.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Ketamine effect on Suicidal Ideation and Depression.

    Measured over 4 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Males and females 2. Ages 18-65 3. All races and ethnicities 4. Willing and able to provide informed consent 5. A cutoff score of \>3 on the Beck Scale for Suicidal Ideation 6. \>2 on the Columbia Scale for Suicide Severity Rating Exclusion Criteria: 1. Pregnancy or lactation; women of reproductive potential must have a negative urine pregnancy test 2. Post-partum state (within 2 months of delivery) 3. Homicide risk as determined by clinical interview 4. Any of the following Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnoses: 1. Any current primary psychotic disorder 2. Acute intoxication or withdrawal from alcohol or any other substance of abuse, as determined by clinical interview and urine drug screen except opioids 3. use of any hallucinogen (except cannabis), in the last month 4. Any dissociative disorder 5. Pervasive developmental disorder 6. Cognitive disorder 7. Cluster A personality disorder 8. Anorexia nervosa. 5. Treatment with any medication known to affect the N-methyl-D-aspartate (NMDA) receptor system (e.g., lamotrigine, acamprosate, memantine, riluzole, or lithium) 6. Any known hypersensitivity or serious adverse effect with ketamine 7. Any clinically-significant medication or condition that would preclude the use of ketamine

Where

1 study site

FacilityCityRegionCountry
University of CincinnatiCincinnatiOhioUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT02183272 on ClinicalTrials.gov →

Last updated in the registry 2016-08-05. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Recruiting in

All 2 trials from University of Cincinnati →